Asked by: Martyn Day (Scottish National Party - Linlithgow and East Falkirk)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 29 February 2024 to Question 15459 on Diabetes: Medical Equipment, what the evidential basis is for growth in the prescribing of diabetes technology for people living with type 2 diabetes.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The National Institute for Care and Excellence (NICE) published a recommendation in March 2023 that people with type 2 diabetes, who have multiple daily insulin injections and a condition or disability that means they cannot use capillary blood glucose monitoring, should be offered Continuous Glucose Monitoring (CGM) technology, either real time or intermittent, to support self-monitoring.
The NICE also recommended in March 2023 that adults with insulin-treated type 2 diabetes having their blood glucose monitored by a care worker or healthcare professional, are offered CGM. The rationale is that CGM can help to improve glycaemic control in adults with type 2 diabetes who use insulin.
Asked by: Martyn Day (Scottish National Party - Linlithgow and East Falkirk)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether her Department is taking steps to increase uptake in the use of monitoring technologies by patients with diabetes.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The National Institute for Health and Care Excellence (NICE) has recently issued clinical guidelines in relation to the management of insulin dependent diabetes, covering patients living with type 1 and insulin dependent type 2 diabetes. This includes devices to support blood glucose monitoring. These recommendations are now being implemented by integrated care boards (ICBs).
On 19 December 2023, NICE published its final recommendation on the hybrid closed loop system for people with type 1 diabetes. NICE has agreed with NHS England that all children and young people, women who are pregnant or planning a pregnancy, and those people who already have an insulin pump will be first to be offered a hybrid closed loop system as part of a 5-year roll-out plan. NHS England has set out priorities for access, to help reduce healthcare inequalities through their implementation plan.
Responsibility for the delivery of services and the implementation of NICE recommendations rests with the appropriate National Health Service commissioner. As diabetes care is commissioned by local ICBs, they are responsible for developing commissioning policies. ICBs must pay due regard to NICE guidance, however local decision making applies in terms of deciding whether to utilise their funding to implement the recommendation or not.
Correspondence Apr. 23 2024
Committee: International Development Committee (Department: Department for International Development)Found: 70/30 (70% Human Insulin Isophan Protamine + 30% Soluble Human Insulin) - Cartridge (3ml)Amp 5000 41Insulin
Apr. 29 2024
Source Page: Letters and medicine recalls sent to healthcare professionals in March 2024Found: March 2024 DIRECT HEALTHCARE PROFESSIONAL COMMUNICATION Fiasp ® FlexTouch® (fast-acting insulin
Asked by: Regan, Ash (Alba Party - Edinburgh Eastern)
Question
To ask the Scottish Government what action it is taking to address the reportedly significant waiting times for access to diabetes technology, such as insulin pumps and continuous glucose monitoring systems, for people with type 1 diabetes across Scotland, including in NHS Lothian, and what steps are being taken to meet the national targets and align with reported advancements in NHS England.
Answered by Minto, Jenni - Minister for Public Health and Women's Health
The Scottish Government’s Diabetes Improvement Plan contains a key commitment to further increase access to existing and emerging diabetes technologies.
Between 2016 and 2022, we invested £29.6 million of additional funding specifically to support the increased provision of insulin pumps and continuous glucose monitors (CGMs) and emerging technologies such as closed loop systems.
We have also invested a further £350,000 through the Accelerated National Innovation Adoption pathway to help roll out the technology faster and more efficiently across Scotland. A key focus of this project is reducing regional variation and making access to technology more equitable across Scotland.
We continue to work closely the Diabetes Managed Clinical Networks (MCNs) within each Board, including NHS Lothian, to identify and resolve any issues raised by NHS Boards regarding accessing diabetes technologies, to ensure that all available resource is targeted to support the needs of local populations.
Dec. 09 2008
Source Page: Diabetes in the NHS: commissioning and providing specialist services. 26 p.Found: , insulin pumps and the development ofaccredited patient education.
Asked by: Martyn Day (Scottish National Party - Linlithgow and East Falkirk)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether her Department plans to take steps to ensure that every person with diabetes has access to medical technology that helps them manage their condition.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
Standard care for type 1 diabetes involves regularly measuring blood glucose levels by self-monitoring, blood testing, or by using a continuous glucose monitor, real-time or intermittently scanned.
The NHS Long Term Plan committed that 20% of people with type 1 diabetes would benefit from life changing flash glucose monitors. Data to quarter three of 2022/23 shows that 73% of people with type 1 diabetes were prescribed flash glucose monitoring, against the 20% target.
In March 2023 the National Institute for Health and Care Excellence (NICE) recommended that insulin dependent patients with type 2 diabetes should also benefit from flash or continuous glucose monitoring devices. We are now starting to see a growth in prescribing within the type 2 diabetes patient group.
On 19 December 2023 the NICE published its final recommendation on the hybrid closed loop system. The NICE has agreed with NHS England that all children and young people, women who are pregnant or planning a pregnancy, and those people who already have an insulin pump will be the first to be offered a hybrid closed loop system, as part of a five-year roll-out plan. Access to hybrid closed loop systems will be through a five-year phased roll out, in line with NHS England’s implementation plans.
Dec. 03 2009
Source Page: Tables showing admissions where the primary diagnosis was diabetic ketoacidosis or hypoglycaemia with a secondary diagnosis of diabetes: by type of diabetes, age, sex and strategic health authority from 2004/05 to 2008/09. 12 p.Found: diabetes mellitus with ketoacidosisE11.1 Non-insulin-dependent diabetes mellitus with ketoacidosisE12.1
Mentions:
1: Lord Pickles (Con - Life peer) He went to tell the Russian authorities that he was running low, and he was told, “We do not supply insulin - Speech Link
Asked by: Boyack, Sarah (Scottish Labour - Lothian)
Question
To ask the Scottish Government what percentage of patients with diabetes it anticipates will be offered the option to transfer to a hybrid closed loop system as part of their insulin management during the financial year 2024-25, broken down by NHS board.
Answered by Minto, Jenni - Minister for Public Health and Women's Health
It is for each individual NHS Board to determine how they plan to meet the needs and priorities of their local populations. The Scottish Government is committed to increasing access to diabetes technologies. We are continuing to work with key stakeholders to determine the best way to do this and how to fund it.